Emerging Risk Profile of Lung Cancer Therapy: Diffuse Alveolar Hemorrhage from Osimertinib

Osimertinib is an oral epithelial growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used primarily in the treatment of metastatic non-small cell lung cancer. It is usually well tolerated with less than 5% of patients developing significant pulmonary toxicity from the medication, typically...

Descripción completa

Detalles Bibliográficos
Autores principales: Forte, Michael J., Sangani, Rahul G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701301/
https://www.ncbi.nlm.nih.gov/pubmed/31467750
http://dx.doi.org/10.1155/2019/6185943

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701301/
https://www.ncbi.nlm.nih.gov/pubmed/31467750
http://dx.doi.org/10.1155/2019/6185943

Ejemplares similares